Evidence map›Paper›PMID 35460360›Full record

ArticleCancer chemotherapy and pharmacology2022

An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.

Oula C Mansour, Abraham Nudelman, Ada Rephaeli, Don R Phillips, Suzanne M Cutts, Benny J Evison

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Oula C MansourDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia.
Abraham NudelmanChemistry Department, Bar-Ilan University, 52900, Ramat-Gan, Israel.
Ada RephaeliSackler Faculty of Medicine, Felsenstein Medical Research Center, Tel-Aviv University, 49100, Petach-Tikva, Israel.
Don R PhillipsDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia.
Suzanne M CuttsDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia. s.cutts@latrobe.edu.au.
Benny J EvisonDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia. benny.evison@nyrada.com.ORCID http://orcid.org/0000-0001-5477-8721
La Trobe University · AUBar-Ilan University · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePixantrone is a synthetic aza-anthracenedione currently used in the treatment of non-Hodgkin's lymphoma. The drug is firmly established as a poison of the nuclear enzyme topoisomerase II, however, pixantrone can also generate covalent drug-DNA adducts following activation by formaldehyde. While pixantrone-DNA adducts form proficiently in vitro, little evidence is presently at hand to indicate their existence within cells. The molecular nature of these lesions within cancer cells exposed to pixantrone and formaldehyde-releasing prodrugs was characterized along with the cellular responses to their formation.

methodsIn vitro crosslinking assays, [

resultsPixantrone-DNA adducts were not detectable in MCF-7 breast cancer cells exposed to [

conclusionsThe features unique to pixantrone-DNA adducts may be leveraged to enhance cancer cell kill and may be used to guide the design of pixantrone analogues that generate adducts with more favorable anticancer properties.

Indexed as

NeoplasmsProdrugsDNA AdductsDNA Topoisomerases, Type IIFormaldehydeHumansIsoquinolinesDNA AdductsDNA Topoisomerases, Type IIFormaldehydeIsoquinolinespixantroneProdrugsDNA adductFormaldehydeMechanism of actionPixantroneTopoisomerase II

Identifiers

PMID35460360
OpenAlexW4224315887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.